<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00253474</url>
  </required_header>
  <id_info>
    <org_study_id>050232</org_study_id>
    <secondary_id>05-C-0232</secondary_id>
    <secondary_id>NCI-P6670</secondary_id>
    <secondary_id>CDR0000448811</secondary_id>
    <nct_id>NCT00253474</nct_id>
    <nct_alias>NCT00156754</nct_alias>
  </id_info>
  <brief_title>PEG-Interferon Alfa-2b in Treating Young Patients With Plexiform Neurofibroma</brief_title>
  <official_title>A Phase I Trial of Peginterferon Alfa-2b (PEG-Intron) for Plexiform Neurofibromas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institutes of Health Clinical Center (CC)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      RATIONALE: PEG-interferon alfa-2b may interfere with the growth of tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of PEG-interferon&#xD;
      alfa-2b in treating young patients with plexiform neurofibroma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the maximum tolerated dose of PEG-interferon alfa-2b in patients with&#xD;
           unresectable plexiform neurofibroma. (Dose escalation portion of study closed to accrual&#xD;
           as of 2/2005.)&#xD;
&#xD;
        -  Determine the toxicity profile of this drug in these patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Obtain, preliminary, information about the efficacy of this drug in these patients.&#xD;
&#xD;
        -  Evaluate the growth rate of plexiform neurofibroma using volumetric MRI analysis in&#xD;
           patients treated with this drug.&#xD;
&#xD;
        -  Evaluate the impact of this drug, in terms of &quot;worst symptom&quot; score, in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation, multicenter study. (Dose-escalation portion of the study&#xD;
      closed to accrual as of 2/2005.)&#xD;
&#xD;
      Patients receive PEG-interferon alfa-2b subcutaneously once weekly for 2 years in the absence&#xD;
      of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of PEG-interferon alfa-2b until the maximum&#xD;
      tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 1&#xD;
      of 6 patients experience dose-limiting toxicity. A total of 12 patients receive treatment at&#xD;
      the MTD.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 6 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 36 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Neoplasm of Uncertain Malignant Potential</condition>
  <condition>Unspecified Childhood Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PEG-interferon alfa-2a</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of plexiform neurofibroma which is progressive, symptomatic, or life&#xD;
             threatening and for which there is no other standard medical management or surgical&#xD;
             option&#xD;
&#xD;
          -  Histologic confirmation of tumor is not required in the presence of consistent&#xD;
             clinical and radiographic findings provided the following are true:&#xD;
&#xD;
               -  No clinical observation or scan suggestive of malignant transformation&#xD;
&#xD;
               -  Meets ≥ 1 of the following diagnostic criteria for neurofibroma type 1 (NF1):&#xD;
&#xD;
                    -  Six or more cafe-au-lait spots (&gt; 0.5 cm in prepubertal patients or &gt; 1.5 cm&#xD;
                       in post pubertal patients)&#xD;
&#xD;
                    -  Freckling in axilla or groin&#xD;
&#xD;
                    -  Optic glioma&#xD;
&#xD;
                    -  Two or more Lisch nodules&#xD;
&#xD;
                    -  A distinctive bony lesion (e.g., dysplasia of the sphenoid bone, dysplasia,&#xD;
                       or thinning of long bone cortex)&#xD;
&#xD;
                    -  A first degree relative with NF1&#xD;
&#xD;
          -  No history of malignant peripheral nerve sheath tumor&#xD;
&#xD;
          -  No active visual pathway glioma&#xD;
&#xD;
          -  No active brain tumor or brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 12 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count &gt; 1,500/mm^3&#xD;
&#xD;
          -  Hemoglobin &gt; 10 g/dL&#xD;
&#xD;
          -  Platelet count &gt; 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin &lt; 1.5 mg/dL&#xD;
&#xD;
          -  SGPT ≤ 2 times upper limit of normal&#xD;
&#xD;
          -  No significant hepatic dysfunction&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine based on age as follows:&#xD;
&#xD;
               -  ≤ 0.8 mg/dL (for patients age 5 years and under)&#xD;
&#xD;
               -  ≤ 1.0 mg/dL (for patients age 6 to 10 years)&#xD;
&#xD;
               -  ≤ 1.2 mg/dL (for patients age 11 to 15 years)&#xD;
&#xD;
               -  ≤ 1.5 mg/dL (for patients age 16 to 21 years) OR&#xD;
&#xD;
          -  Creatinine clearance ≥ 70 mL/min&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No significant cardiac dysfunction&#xD;
&#xD;
          -  No severe cardiovascular disease&#xD;
&#xD;
          -  No cardiac arrhythmia requiring chronic treatment&#xD;
&#xD;
          -  No congestive heart failure&#xD;
&#xD;
          -  No symptomatic ischemic heart disease&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No significant pulmonary dysfunction&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No serious infection&#xD;
&#xD;
          -  No other significant unrelated systemic illness&#xD;
&#xD;
          -  No significant organ dysfunction&#xD;
&#xD;
          -  No other malignancy except surgically cured nonmelanoma skin cancer or carcinoma in&#xD;
             situ of the cervix&#xD;
&#xD;
          -  No history of severe psychiatric condition or psychiatric disorder requiring&#xD;
             hospitalization&#xD;
&#xD;
          -  No history of suicidal ideation or attempt&#xD;
&#xD;
          -  No thyroid dysfunction unresponsive to therapy&#xD;
&#xD;
          -  No uncontrolled diabetes mellitus&#xD;
&#xD;
          -  No history of HIV positivity&#xD;
&#xD;
          -  No alcohol or drug abuse&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No concurrent immunotherapy&#xD;
&#xD;
          -  No concurrent colony-stimulating factors (e.g., erythropoietin or filgrastim [G-CSF])&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No concurrent chemotherapy for this disease&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  No concurrent chronic systemic corticosteroids&#xD;
&#xD;
          -  No concurrent hormonal therapy for this disease&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy for this disease&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Prior surgery allowed provided it has been at least 21 days since surgery and there is&#xD;
             presence of residual tumor&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Recovered from prior therapy&#xD;
&#xD;
          -  More than 30 days since prior investigational agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brigitte C. Widemann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010-2970</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Memorial Hospital - Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Jakacki RI, Dombi E, Potter DM, Goldman S, Allen JC, Pollack IF, Widemann BC. Phase I trial of pegylated interferon-alpha-2b in young patients with plexiform neurofibromas. Neurology. 2011 Jan 18;76(3):265-72. doi: 10.1212/WNL.0b013e318207b031.</citation>
    <PMID>21242495</PMID>
  </results_reference>
  <verification_date>March 2012</verification_date>
  <study_first_submitted>November 11, 2005</study_first_submitted>
  <study_first_submitted_qc>November 11, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2005</study_first_posted>
  <last_update_submitted>March 28, 2012</last_update_submitted>
  <last_update_submitted_qc>March 28, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 29, 2012</last_update_posted>
  <keyword>neoplasm of uncertain malignant potential</keyword>
  <keyword>unspecified childhood solid tumor, protocol specific</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neurofibroma</mesh_term>
    <mesh_term>Neurofibroma, Plexiform</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Interferon alpha-2</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

